Skip to content

Study · Animal study (in vivo) · mouse · 2006

5 results

Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis.

Petri S, Kiaei M, Damiano M, Hiller A, Wille E, Manfredi G, Calingasan NY, Szeto HH, Beal MF

Journal of neurochemistry1 Aug 2006Cited by 133 (Europe PMC)

PMID16895581 (opens in a new tab)DOI10.1111/j.1471-4159.2006.04018.x (opens in a new tab)PepBankPUB-16895581
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In G93A mice, a model of ALS, daily SS‑31 (5 mg/kg) from 30 days of age significantly improved survival.

    In plain wordsIn mice with an ALS-like disease, daily SS‑31 injections improved survival.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSurvival
    Study

    mousen: not reported in source

    G93A mouse model of ALS
    Outcome group
    Mortality · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Daily intraperitoneal injections of SS-31 (5 mg/kg), starting at 30 days of age, led to a significant improvement in survival and motor performance.
    1 context sentence
    Summary · context
    In the present study, we investigated a novel peptide antioxidant (SS-31) targeted to the inner mitochondrial membrane for its therapeutic effects both in vitro and in vivo in the G93A mouse model of amyotrophic lateral sclerosis (ALS).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In G93A mice, a model of ALS, daily SS‑31 (5 mg/kg) from 30 days of age significantly improved motor performance.

    In plain wordsIn mice with an ALS-like disease, daily SS‑31 injections improved movement performance.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMotor performance
    Study

    mousen: not reported in source

    G93A mouse model of ALS
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Daily intraperitoneal injections of SS-31 (5 mg/kg), starting at 30 days of age, led to a significant improvement in survival and motor performance.
    1 context sentence
    Summary · context
    In the present study, we investigated a novel peptide antioxidant (SS-31) targeted to the inner mitochondrial membrane for its therapeutic effects both in vitro and in vivo in the G93A mouse model of amyotrophic lateral sclerosis (ALS).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In G93A mice, SS‑31 treatment decreased cell loss in the lumbar spinal cord compared with vehicle treatment.

    In plain wordsIn mice with an ALS-like disease, SS‑31 reduced nerve cell loss in the spinal cord compared with vehicle.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCell loss in lumbar spinal cord
    Study

    mousen: not reported in source

    G93A mouse model of ALS
    Comparator
    Vehicle-treated G93A mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    In comparison with vehicle-treated G93A mice, SS-31-treated mice showed a decreased cell loss and a decrease in immunostaining for markers of oxidative stress in the lumbar spinal cord.
    1 context sentence
    Summary · context
    In the present study, we investigated a novel peptide antioxidant (SS-31) targeted to the inner mitochondrial membrane for its therapeutic effects both in vitro and in vivo in the G93A mouse model of amyotrophic lateral sclerosis (ALS).
  4. 04AnimalAnimal study (in vivo)Mechanism

    In G93A mice, SS‑31 treatment decreased immunostaining for oxidative stress markers in the lumbar spinal cord compared with vehicle treatment.

    In plain wordsIn mice with an ALS-like disease, SS‑31 lowered signs of oxidative stress in the spinal cord compared with vehicle.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseOxidative stress markers in lumbar spinal cord
    Study

    mousen: not reported in source

    G93A mouse model of ALS
    Comparator
    Vehicle-treated G93A mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    In comparison with vehicle-treated G93A mice, SS-31-treated mice showed a decreased cell loss and a decrease in immunostaining for markers of oxidative stress in the lumbar spinal cord.
    1 context sentence
    Summary · context
    In the present study, we investigated a novel peptide antioxidant (SS-31) targeted to the inner mitochondrial membrane for its therapeutic effects both in vitro and in vivo in the G93A mouse model of amyotrophic lateral sclerosis (ALS).
  5. 05LabIn vitro (cells)Activity measurement

    In neuronal cells expressing wild-type or mutant SOD1, SS‑31 protected against hydrogen peroxide-induced cell death.

    In plain wordsIn cells, SS‑31 protected nerve cells against cell death caused by hydrogen peroxide.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseHydrogen peroxide-induced cell death
    Study

    n: not reported in source

    Neuronal cells stably transfected with wild-type or mutant SOD1
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SS-31 protected against cell death induced by hydrogen peroxide in vitro in neuronal cells stably transfected with either wild-type or mutant Cu/Zn superoxide dismutase (SOD1).
    1 context sentence
    Summary · context
    In the present study, we investigated a novel peptide antioxidant (SS-31) targeted to the inner mitochondrial membrane for its therapeutic effects both in vitro and in vivo in the G93A mouse model of amyotrophic lateral sclerosis (ALS).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.